^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Fotivda (tivozanib) (VEGFR-2 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    European Medicines Agency
    Published date:
    08/24/2017
    Excerpt:
    Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Excerpt:
    FOTIVDA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    The Oncologist
    Title:

    Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3

    Published date:
    12/28/2022
    Excerpt:
    Out of 350 patients, 172 (83:89, tivozanib:sorafenib) had received prior treatment with axitinib in TIVO-3. In this subgroup, PFS was 5.5 months with tivozanib and 3.7 months with sorafenib (HR 0.68). RR was 13% and 8% favoring tivozanib.
    DOI:
    https://doi.org/10.1093/oncolo/oyac255
    Trial ID:
    TIVO-3
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Elsevier
    Title:

    Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma

    Published date:
    09/13/2020
    Excerpt:
    Given its activity and distinct tolerability profile, tivozanib represents a treatment option for patients with previously treated mRCC.
    DOI:
    https://doi.org/10.1016/j.eururo.2020.08.007
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Lancet Oncol
    Title:

    Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

    Published date:
    01/01/2020
    Excerpt:
    Median progression-free survival was significantly longer with tivozanib (5·6 months, 95% CI 5·29–7·33) than with sorafenib (3·9 months, 3·71–5·55; hazard ratio 0·73, 95% CI 0·56–0·94; p=0·016)....study showed that tivozanib as third-line or fourth-line therapy improved progression-free survival and was better tolerated compared with sorafenib in patients with metastatic renal cell carcinoma.
    DOI:
    10.1016/S1470-2045(19)30735-1
    Trial ID:
    TIVO-3